Atossa Therapeutics closed at $2.24 on Nov 4, down 3.68%, 83.5% below its 52-week closing high. Volume of 19.5K shares was 0.21× its 20-day average (below normal).
Split-adjusted performance: -8.4% over one month, -61.3% over six months, -82.7% over one year.
Short interest was 683.5K shares at the Oct 15 settlement, down 13.3% from the prior report (7.7% of float, 5.8 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ATOSAtossa Therapeutics | $2.24 | −3.68% | −61.3% | — | — | — | $22.4M | |
| MIRAMIRA Pharmaceuticals | $0.5411 | +4.51% | −45.9% | — | — | — | $22.7M | Compare |
| CRVOCervoMed | $1.53 | −1.61% | −60.2% | −100.0% | — | — | $23.1M | Compare |
| EDSAEdesa Biotech | $2.20 | −3.51% | −85.3% | — | — | — | $21.2M | Compare |
| TXMDTherapeuticsMD | $1.82 | +2.25% | −10.3% | −8.7% | 17.8% | — | $21.1M | Compare |
| AYTUAYTU BioPharma | $1.91 | −1.04% | −25.4% | +6.4% | −0.1% | — | $20.8M | Compare |
| SHPHShuttle Pharmaceuticals Holdings | $5.34 | +3.69% | −31.5% | — | — | — | $25.4M | Compare |
| CPHIChina Pharma Holdings | $0.5950 | −2.33% | +12.8% | −7.5% | −153.8% | — | $25.6M | Compare |
| IGCIGC Pharma | $0.1882 | +1.18% | −40.9% | −19.2% | −1107.9% | — | $19.5M | Compare |
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
